Reports Q1; CNTY-813 And CNTY-308 On Track To Enter Clinic This Year

Research evidence excerpt

Reports Q1; CNTY-813 And CNTY-308 On Track To Enter Clinic This Year

Biotechnology

Century Therapeutics

TD SECURITIES (USA) LLC EARNINGS UPDATE

May 13, 2026

Price: $2.29 (05/12/2026) Reports Q1; CNTY-813 And CNTY-308 On

Price Target: NA Track To Enter Clinic This Year

BUY (1)

ESG SCORE: 60/100

Phil Nadeau, Ph.D. THE TD COWEN INSIGHT

646 562 1336

CNTY-813, immune-engineered allogenic cell therapy for T1D, remains on track to IND in

philip.nadeau@tdsecurities.com

Q4:26 with initial data in H2:27. Century plans to present preclinical data highlighting mfg.

Salvatore Caruso, Ph.D. scalability + Allo-Evasion platform at ADA in June. CNTY-308 (iPSC-derived CD19 CAR-T) is

646 562 1315 moving through IND-enabling studies with plans to initiate a trial by YE. $217MM in cash to

salvatore.caruso@tdsecurities.com

fund ops into Q1:29. Remain at Buy.

Key Data

Symbol NASDAQ: IPSC CNTY-813: Immune-Engineered Allogenic Cell Therapy For T1D On Track To IND In Q4:26

Beta: 1.56 And Read Out In H2:27; Preclinical Data To Be Presented At ADA

52-Week Range: $2.94-$0.46

Century's lead program, CNTY-813, is an allogenic, iPSC-derived, immune-engineered beta

Market Cap: $412.3MM

islet cell therapy for the treatment of T1D. Century has shown that iPSC-derived beta islet

Net Debt (MM): $(217.0) cells bearing Allo-Evasion 5.0 genetic edits can produce robust and persistent (6+ months)

Cash/Share: $(1.21) glycemic regulation in animal models of T1D on par with their unedited counterparts. Critically,

Dil. Shares Out (MM): 193.5 the company has generated a GMP master cell bank containing all the desired Allo-Evasion

Enterprise Value

$123.9 5.0 genetic edits, which include MHC I/II interruption, a CD300a TASR insertion, and an

(MM):

BV/Share: $1.82 IgG cell-surface degrading enzyme (IdeS) insertion.